Philips Partnership to Expand Veteran Lung Screening for bioAffinity, Sales Accelerate
BIAF sits 20% above its 52-week low of $0.693 on light trading volume (0.3× avg).
Summary
bioAffinity Technologies announced a significant partnership with Philips and 4DMedical to enhance lung cancer screening for U.S. veterans using its CyPath® Lung diagnostic test. This collaboration is a major positive for the company, which recently closed a $3.2 million public offering to address its critical cash runway, reported to extend only through June 2026 in its Q1 10-Q filing. The company also reported continued strong commercial traction, with ordering physician offices increasing 69% from Q1 2025 to Q1 2026. For a micro-cap biotech facing a going concern warning, this partnership provides crucial validation and a potential pathway to significantly expand market access and revenue for CyPath® Lung.
At the time of this announcement, BIAF was trading at $0.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $0.69 to $13.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.